Avantor, Inc. (NYSE:AVTR) Shares Bought by Amalgamated Bank

Amalgamated Bank boosted its stake in shares of Avantor, Inc. (NYSE:AVTR) by 0.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 325,096 shares of the company’s stock after purchasing an additional 1,126 shares during the period. Amalgamated Bank’s holdings in Avantor were worth $6,850,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Bank of New York Mellon Corp grew its stake in shares of Avantor by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 4,830,719 shares of the company’s stock worth $101,783,000 after purchasing an additional 68,598 shares during the period. Impax Asset Management Group plc boosted its holdings in Avantor by 30.8% during the fourth quarter. Impax Asset Management Group plc now owns 1,789,610 shares of the company’s stock worth $37,707,000 after buying an additional 421,252 shares in the last quarter. South Dakota Investment Council acquired a new stake in Avantor during the fourth quarter valued at $948,000. VisionPoint Advisory Group LLC increased its holdings in Avantor by 5.2% in the fourth quarter. VisionPoint Advisory Group LLC now owns 156,767 shares of the company’s stock valued at $3,323,000 after buying an additional 7,771 shares in the last quarter. Finally, First Bank & Trust increased its stake in shares of Avantor by 6.3% in the 4th quarter. First Bank & Trust now owns 18,899 shares of the company’s stock valued at $398,000 after purchasing an additional 1,117 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

AVTR has been the subject of several recent analyst reports. Raymond James reissued an “outperform” rating and issued a $24.00 price target (down previously from $26.00) on shares of Avantor in a report on Monday, February 10th. UBS Group reaffirmed a “neutral” rating and issued a $25.00 price target (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Barclays cut their price objective on Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Stifel Nicolaus decreased their target price on Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Finally, Morgan Stanley dropped their price target on Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Avantor presently has a consensus rating of “Moderate Buy” and an average target price of $25.92.

Avantor Price Performance

Shares of AVTR stock opened at $17.22 on Thursday. The firm’s 50-day moving average is $20.69 and its two-hundred day moving average is $22.79. Avantor, Inc. has a 12 month low of $17.14 and a 12 month high of $28.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.07 and a quick ratio of 0.70. The company has a market capitalization of $11.73 billion, a PE ratio of 16.56, a price-to-earnings-growth ratio of 1.55 and a beta of 1.28.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.17% and a net margin of 10.49%. During the same period last year, the business earned $0.22 earnings per share. Analysts predict that Avantor, Inc. will post 1.06 earnings per share for the current year.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.